EDAP TMS S.A. to Release 2007 Second Quarter Results LYON, France , Aug. 16 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer and the international leader in the development, production, and

PR Marketing & Education Programs to Expand

EDAP pushes French reimbursement case

EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer LYON, France , Aug. 17 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, is

EDAP Revises Termination Agreement With HealthTronics LYON, France , July 16 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, reports today an update to its Termination Agreement with HealthTronics,

HIFU Resource Center Online at www.urotoday.com EDAP and the Ablatherm-HIFU now have a HIFU section in the most popular urology web site in the world : http://www.urotoday.com . Urotoday.com is a scientific web site serving urologists visited by more than 50,000 urologists every month worldwide.

Dedicated Press Conference Organized at Edouard Herriot Hospital, Lyon, France

Strong North American Focus, Expertise to Augment US Study Program

Official Report Ranks Ablatherm-HIFU User Sites Among Top French Public Hospitals

EDAP Adds Malaysia, Korea to France as Exclusive Markets and Secures Worldwide Exclusivity When StoneBreaker™ Offered with EDAP's Devices